Medtide Inc

03880

Company Profile

  • Business description

    Medtide Inc offers full-cycle services ranging from early-stage discovery, preclinical research and clinical development to commercial-stage production. It mainly provide (i) CRO services, namely peptide NCE discovery synthesis; and (ii) CDMO services, namely peptide CMC development and commercial manufacturing. Its services focus on providing customers with APIs rather than drug products.

  • Contact

    No. 69, 12 Street
    Qiantang District
    Zhejiang
    Hangzhou
    CHN

    https://www.medtideinc.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    522

Stocks News & Analysis

stocks

Potentially catastrophic ruling for ASX company

We raise our risk and uncertainty rating to reflect the impact of the ruling.
stocks

4 charts on Nvidia’s record $4 trillion market cap

Shares of the semiconductor giant have rocketed 280% over the past two years amid the AI boom.
stocks

Could merger breathe new life into struggling ASX asset manager?

Platinum’s board voted unanimously in favour of a merger we expect would be value accretive.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,815.305.00-0.06%
CAC 407,793.9835.31-0.45%
DAX 4024,042.32212.99-0.88%
Dow JONES (US)44,371.51279.13-0.63%
FTSE 1008,973.6632.540.36%
HKSE24,203.3263.750.26%
NASDAQ20,585.5345.14-0.22%
Nikkei 22539,459.62110.06-0.28%
NZX 50 Index12,678.697.99-0.06%
S&P 5006,259.750.000.00%
S&P/ASX 2008,570.409.70-0.11%
SSE Composite Index3,519.659.470.27%

Market Movers